Werth Lab
@werthlab
Followers
549
Following
642
Media
66
Statuses
383
The Autoimmune Skin Disease Unit @Penn Lab of Dr. Victoria Werth #dermatomyositis #lupus #blistering Managed by lab members
Philadelphia, PA
Joined April 2021
RT @HealioRheum: 📢 “There has not been a single approved drug for cutaneous #lupus in 75 years,” said Dr. Victoria P. Werth @werthlab. Rea….
0
2
0
Development and Evaluation of the #Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials in @theJIDJournal JID Innovations
jidinnovations.org
The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In...
0
0
0
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with #dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial in @TheLancet
thelancet.com
Dazukibart resulted in a pronounced reduction in disease activity and was generally well tolerated, supporting IFNβ inhibition as a highly promising therapeutic strategy in adults with dermatomyosi...
0
0
1
Erythema variation in #dermatomyositis across subtypes and racial groups: importance of outcome measure for dermatomyositis clinical trials in @BrJDermatol
academic.oup.com
Two measurement tools are currently used to assess skin disease activity in dermatomyositis (DM) clinical trials: the Cutaneous Dermatomyositis Disease Are
1
1
1
Risk of interstitial lung disease in adult patients with #dermatomyositis treated with methotrexate: A retrospective analysis of a prospective cohort in @JAADjournals
0
0
1
#Smoking status is a negative predictor of six-month cutaneous #lupus activity trends: A prospective cohort study in @JAADjournals by Tyler Cepica and investigators from the Chong Lab @UTSWDerm and from our group!
0
1
6
Subtype and Racial Erythema Variation for Cutaneous #Lupus Trials by Lillian Xie and others from our group in @JAMADerm #DermTwitter.
jamanetwork.com
This cross-sectional study assesses cutaneous lupus erythematosus severity scores by disease subtype and patient self-reported race to determine whether differences affect eligibility for erythema...
0
1
4
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial in @ACR_Journals
acrjournals.onlinelibrary.wiley.com
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. ...
0
0
0
Clinical Characteristics of Anti‐Synthetase Syndrome: Analysis From the Classification Criteria for Anti‐Synthetase Syndrome Project in @ACR_Journals
acrjournals.onlinelibrary.wiley.com
Objective Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical...
0
0
2
Effect of iberdomide on cutaneous manifestations in systemic #lupus erythematosus: A randomized phase 2 clinical trial. In @JAADjournals
jaad.org
Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos.
0
0
3
Pathophysiology of Bullous #Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review) @AdvancesTherapy .
link.springer.com
Advances in Therapy - Bullous pemphigoid (BP) is an autoimmune blistering disease that most often affects elderly individuals and has a significant negative impact on quality of life. The disease...
0
0
1
Long-Term Safety and Efficacy of #Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with #Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study - JID Innovations @theJIDJournal
jidinnovations.org
Dermatomyositis (DM) is a rare autoimmune condition involving skin manifestations often resistant to standard treatments such as immunosuppressants and antimalarials. Biopsies show elevated inflamm...
0
0
0
We are at #SID2025 @SocInvestDerm! We will be presenting several abstracts, tomorrow (5/8/25), looking forward to seeing you there!
0
0
5
Join us June 7 for a session where patients and experts will discuss the importance of #lupus clinical trials. The session will include a catered lunch and time to socialize with other lupus patients in attendance. Mark your calendars and be part of this important discussion!
0
0
3
Please join us for a special discussion on living with skin #lupus on YouTube or on Facebook Live! @blackdoctor_org
0
0
1
Members of the Werth lab were awarded several research awards by the Philadelphia Dermatologic Society for research on autoimmune skin diseases!
0
1
13
RT @MIHRAfoundation: What a GREAT day! Thank you for AMAZING contributions! Rare Disease Day Conference rescue #TOGETHERNESS #MIHRA partne….
0
4
0
0
2
0
RT @MIHRAfoundation: Thank you @werthlab for a ✨️Brilliant✨️ #MIHRA Global Case Conference!.Thanks to all who attended live from 5 continen….
mihrafoundation.org
MIHRA Global Case Conference is an opportunity for the community to examine, discuss and deepen knowledge of disease natural history, clinical practice patterns, diagnosis, recognition of complicat...
0
2
0
RT @pedrommcmachado: 🚨 Final chance to register! 🚨. Join Dr. Vicky Werth (@werthlab) for an eye-opening discussion on autoimmunity and the….
0
2
0